Table 1 Descriptive statistics for total cohort and two subgroups stratified by preoperative CA19–9 alteration
Total cohort | Subgroups | P value | |||
|---|---|---|---|---|---|
Normal | Responder | Non-responder | |||
Number | 240 | 49 | 33 | 158 | |
Gender (n) | |||||
Male:Female | 119:121 | 23:26 | 16:17 | 80:78 | 0.895 |
Age (year) | |||||
Median (range) | 67 (36–83) | 65 (38–79) | 68 (36–78) | 66 (41–83) | 0.881 |
Pre-neoadjuvant therapy CA19–9 value (U/ml) | |||||
Median (range) | 152.7 (2.0–87,100.0) | 12.9 (2.0–36.4) | 84.0 (39.5–1129.0) | 344.8 (32.0–87,100.0) | 0.151 |
Post-neoadjuvant therapy CA19–9 value (U/ml) | |||||
Median (range) | 57.7 (2.0–37,370.0) | 8.5 (2.0–30.0) | 21.0 (8.1–33.0) | 134.5 (38.0–37,370.0) | 0.148 |
% decrease of CA19–9 value (%) | |||||
Median (range) | 53.2 (−100.0–326.4) | 14.7 (− 100.0–100.0) | 75.6 (24.9–90.2) | 54.1 (− 326.4–96.4) | <.0001 |
Post-surgical CA19–9 value (U/ml) | |||||
Median (range) | 18.6 (2.0–3929.4) | 7.0 (2.0–35.0) | 9.3 (4.0–171.0) | 35.1 (3.2–3929.4) | 0.026 |
CA19–9 normalization after surgery, n(%) | |||||
yes | 164 (68) | 49 (100) | 29 (88) | 86 (54) | |
no | 76 (32) | 0 (0) | 4 (12) | 72 (46) | <.0001 |
Post-surgical tumor size (mm) | |||||
Median (range) | 27.0 (8.0–70.0) | 24.5 (8.0–48.0) | 28.0 (10.0–50.0) | 28.0 (10.0–70.0) | 0.026 |
Preoperative drainage, n (%) | |||||
yes | 152 (63) | 35 (71) | 17 (52) | 100 (63) | |
no | 88 (37) | 14 (29) | 16 (48) | 58 (37) | 0.187 |
NCCN resectability, n (%) | |||||
Resectable | 132 (55) | 32 (65) | 21 (64) | 79 (50) | |
Borderline | 108 (45) | 17 (35) | 12 (36) | 79 (50) | 0.096 |
Neoadjuvant therapy, n (%) | |||||
Systematic chemotherapy | 115 (48) | 27 (55) | 11 (33) | 77 (49) | |
Chemoradiotherapy | 125 (52) | 22 (45) | 22 (67) | 81 (51) | 0.145 |
Duration of neoadjuvant therapy (day) | |||||
Median (range) | 69 (13–120) | 69 (22–117) | 71 (44–112) | 68 (13–120) | 0.569 |
RECIST, n (%) | |||||
Complete response | 11 (5) | 4 (8) | 2 (6) | 5 (3) | |
Partial response, | 33 (14) | 11 (23) | 7 (21) | 15 (10) | |
Stable disease | 192 (80) | 33 (67) | 24 (73) | 135 (85) | |
Progressive disease | 4 (1) | 1 (2) | 0 (0) | 3 (2) | 0.096 |
Operation, n (%) | |||||
Pancreaticoduodenectomy | 160 (67) | 33 (67) | 26 (79) | 101 (64) | |
Distal pancreatectomy | 80 (33) | 16 (33) | 7 (21) | 57 (36) | 0.256 |
N classification (UICC), n (%) | |||||
1 | 130 (54) | 24 (49) | 12 (36) | 93 (59) | |
0 | 110 (46) | 25 (51) | 21 (64) | 64 (41) | 0.042 |
Residual tumor, n (%) | |||||
R0 | 205 (85) | 44 (90) | 32 (97) | 129 (82) | |
R1 | 35 (15) | 5 (10) | 1 (3) | 29 (18) | 0.048 |
Adjuvant therapy, n (%) | |||||
yes | 205 (85) | 42 (86) | 27 (82) | 136 (86) | |
no | 35 (15) | 7 (14) | 6 (18) | 22 (14) | 0.826 |
Completion of adjuvant therapy, n (%) | |||||
yes | 139 (67) | 34 (83) | 23 (85) | 82 (59) | |
no | 68 (33) | 7 (17) | 4 (15) | 57 (41) | 0.002 |